Biznes i finanse

Raport bieżący z plikiem 5/2017

Raport bieżący 20/2017

Raport bieżący 31/2017

Raport bieżący 13/2017

Raport bieżący 21/2017

Raport bieżący z plikiem 11/2017

<ul>
<li>Definitive purchase agreement whereby Boston Scientific will acquire Symetis for $435 million in an all cash, up-front payment</li>
</ul>
<ul>
<li>Acquisition of Symetis will expand the treatment offerings for patients with aortic valvular heart disease</li>
</ul>
<ul>
<li>Acquisition projected to close during the second quarter of 2017, subject to customary closing conditions</li>
</ul>
<ul>
<li>Symetis’ IPO launched on Euronext Paris and very well received by the investment community, has been halted</li>
</ul>

Raport bieżący 26/2017

Definitive purchase agreement whereby Boston Scientific will acquire Symetis for $435 million in an all cash, up-front payment; Acquisition of Symetis will expand the treatment offerings for patients with aortic valvular heart disease; Acquisition projected to close during the second quarter of 2017, subject to customary closing conditions; Symetis’ IPO launched on Euronext Paris and very well received by the investment community, has been halted.